Giannis Mountzios(@g_mountzios):Can T-cell engagers create a "tail of the curve" phenomenon in #SCLC, in a way similar to ICIs? Apparently yes! Long-term Follow-up (22m) of the Dellphi-304 trial as published in @Annals_Oncology and reported in #ESMO2026 by @charlesrudin show 30% pts alive at 2 yrs with tarla compared to 15% with chemo. Sustained disease control for ≥52 weeks was observed in 24.4% versus 4.3%. Confirmatory results of prolonged tarla efficacy, giving hope to our patients @SclcSMASHERS @SCLCYIForum @LungCancerEu @YoungLungCancer @myESMO @IASLC @ASCO

2026.11.01 11:00

Can T-cell engagers create a "tail of the curve" phenomenon in #SCLC#, in a way similar to ICIs? Apparently yes! Long-term Follow-up (22m) of the Dellphi-304 trial as published in @Annals_Oncology and reported in #ESMO2026# by @charlesrudin show 30% pts alive at 2 yrs with tarla compared to 15% with chemo. Sustained disease control for ≥52 weeks was observed in 24.4% versus 4.3%. Confirmatory results of prolonged tarla efficacy, giving hope to our patients @SclcSMASHERS @SCLCYIForum @LungCancerEu @YoungLungCancer @myESMO @IASLC @ASCO

커뮤니티로 전달